Indivior Pharmaceuticals Inc. Common Stock vs Moderna, Inc. — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B), while Moderna, Inc. trades at $223.39 (market cap $86.33B). The key difference: Moderna, Inc. is far larger — about 20.7× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Indivior Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Moderna, Inc. for 59 Days on average.
| INDV | MRNA | |
|---|---|---|
Market Cap | $4.18B | $86.33B |
Volume | 1,819,746 | 13,361,426 |
Sector | Health | Health |
52-Week High | $41.83 | $226.30 |
52-Week Low | $24.09 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $4.47B | $82.48B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →